» Articles » PMID: 28261215

TNF Blockade Maintains an IL-10 Phenotype in Human Effector CD4 and CD8 T Cells

Overview
Journal Front Immunol
Date 2017 Mar 7
PMID 28261215
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

CD4 and CD8 effector T cell subpopulations can display regulatory potential characterized by expression of the prototypically anti-inflammatory cytokine IL-10. However, the underlying cellular mechanisms that regulate expression of IL-10 in different T cell subpopulations are not yet fully elucidated. We recently showed that TNF inhibitors (TNFi) promote IL-10 expression in human CD4 T cells, including IL-17 CD4 T cells. Here, we further characterized the regulation of IL-10 expression blockade of TNF signaling or other cytokine/co-stimulatory pathways, in human T cell subpopulations. Addition of the TNFi drug adalimumab to anti-CD3-stimulated human CD4 T cell/monocyte cocultures led to increased percentages of IL-10 cells in pro-inflammatory IL-17, IFNγ, TNFα, GM-CSF, and IL-4 CD4 T cell subpopulations. Conversely, exogenous TNFα strongly decreased IL-10 cell frequencies. TNF blockade also regulated IL-10 expression in CD4 T cells upon antigenic stimulation. Using time course experiments in whole peripheral blood mononuclear cell (PBMC) cultures, we show that TNF blockade maintained, rather than increased, IL-10 cell frequencies in both CD4 and CD8 T cells following stimulation in a dose- and time-dependent manner. Blockade of IL-17, IFNγ, IL-6R, or CD80/CD86-mediated co-stimulation did not significantly regulate IL-10 expression within CD4 or CD8 T cell subpopulations. We show that TNF blockade acts directly on effector CD4 T cells, in the absence of monocytes or CD4 CD25CD127 regulatory T cells and independently of IL-27, resulting in higher IL-10 frequencies after 3 days in culture. IL-10/IL-10R blockade reduced the frequency of IL-10-expressing cells both in the presence and absence of TNF blockade. Addition of recombinant IL-10 alone was insufficient to drive an increase in IL-10 CD4 T cell frequencies in 3-day CD4 T cell/monocyte cocultures, but resulted in increased IL-10 expression at later time points in whole PBMC cultures. Together, these data provide additional insights into the regulation of IL-10 expression in human T cells by TNF blockade. The maintenance of an IL-10 phenotype across a broad range of effector T cell subsets may represent an underappreciated mechanism of action underlying this widely used therapeutic strategy.

Citing Articles

A peptide mimic of SOCS1 modulates equine peripheral immune cells and ocular effector functions : implications for recurrent uveitis.

Stafford L, Plummer C, Smith W, Gibson D, Sharma J, Vicuna V Front Immunol. 2025; 15:1513157.

PMID: 39867889 PMC: 11757128. DOI: 10.3389/fimmu.2024.1513157.


Single cell transcriptomics reveals the cellular heterogeneity of keloids and the mechanism of their aggressiveness.

Cheng X, Gao Z, Shan S, Shen H, Zheng H, Jin L Commun Biol. 2024; 7(1):1647.

PMID: 39702490 PMC: 11659312. DOI: 10.1038/s42003-024-07311-1.


Beyond Suppression: Peripheral T Cell Responses to Vaccination in Inflammatory Bowel Disease Patients Undergoing Anti-Tumor-Necrosis-Factor Therapy.

Qui M, Salazar E Vaccines (Basel). 2024; 12(11).

PMID: 39591183 PMC: 11599089. DOI: 10.3390/vaccines12111280.


Identification of a transcription factor network regulating anti-TNF mediated expression in human CD4+ T cells.

Povoleri G, Ridley M, Marrow R, Lalnunhlimi S, Ryan S, Kelly A Discov Immunol. 2024; 3(1):kyae013.

PMID: 39290825 PMC: 11407445. DOI: 10.1093/discim/kyae013.


Dynamic Boolean modeling of molecular and cellular interactions in psoriasis predicts drug target candidates.

Tsirvouli E, Noel V, Flobak A, Calzone L, Kuiper M iScience. 2024; 27(2):108859.

PMID: 38303723 PMC: 10831929. DOI: 10.1016/j.isci.2024.108859.


References
1.
Fletcher J, Lalor S, Sweeney C, Tubridy N, Mills K . T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol. 2010; 162(1):1-11. PMC: 2990924. DOI: 10.1111/j.1365-2249.2010.04143.x. View

2.
Feldmann M . Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol. 2002; 2(5):364-71. DOI: 10.1038/nri802. View

3.
Hetland M, Christensen I, Tarp U, Dreyer L, Hansen A, Hansen I . Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide.... Arthritis Rheum. 2009; 62(1):22-32. DOI: 10.1002/art.27227. View

4.
Menon B, Gullick N, Walter G, Rajasekhar M, Garrood T, Evans H . Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression. Arthritis Rheumatol. 2014; 66(5):1272-81. PMC: 4158887. DOI: 10.1002/art.38376. View

5.
Taylor P, Feldmann M . Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol. 2009; 5(10):578-82. DOI: 10.1038/nrrheum.2009.181. View